Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$1.64 USD
-0.04 (-2.38%)
Updated Jun 6, 2024 03:59 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNTB 1.64 -0.04(-2.38%)
Will CNTB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTB
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CNTB
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
Pfizer-Connect Biopharma deal for anti-inflammatory agent ends
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
Connect Biopharma price target raised by $1 at H.C. Wainwright, here's why